PET tracer for imaging tau makes progress

By staff writers

September 30, 2022 -- Swiss biopharmaceutical company AC Immune said its development partner, Life Molecular Imaging, is moving its PET tracer PI-2620 for imaging tau in Alzheimer's disease into late-stage clinical development.

AC Immune's proprietary Morphomer platform enabled the discovery of PI-2620 in a research collaboration with Life Molecular. Tau aggregates are an important indicator of neuronal death and correlate strongly with cognitive decline.

As part of the agreement with AC Immune, Life Molecular will make a milestone payment. No other details were disclosed.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking